“Summary Cesca announced some strategic shuffling internally. Cesca will operate as two divisions; Thermogenesis which will handle hardware / device business and Cesca focused on the development of therapeutics. The company will target growth of the device business (which is really what the company was, prior to the merger with Totipotent). We view the device business as a breakeven (at best case) business and not fundamentally attractive (given the high costs and relatively low margins) associated with the business. Management did however talk about adapting the technology to have utility in the CAR-T space. On the Therapeutics side the company highlighted their recent N=17 trial in CLI. The data was published in a peer reviewed journal .”,” the firm’s analyst wrote.
Shares of Cesca Therapeutics (NASDAQ:KOOL) opened at 3.14 on Friday. The stock has a 50 day moving average of $3.15 and a 200-day moving average of $3.04. Cesca Therapeutics has a 12-month low of $2.19 and a 12-month high of $7.39. The company’s market capitalization is $31.04 million.
Cesca Therapeutics (NASDAQ:KOOL) last posted its quarterly earnings results on Monday, February 13th. The biotechnology company reported ($0.35) earnings per share for the quarter. The business had revenue of $4.01 million during the quarter. Cesca Therapeutics had a negative return on equity of 37.44% and a negative net margin of 297.49%. Equities research analysts forecast that Cesca Therapeutics will post ($0.45) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.com-unik.info/2017/05/18/cesca-therapeutics-inc-kool-receives-hold-rating-from-maxim-group.html.
A hedge fund recently raised its stake in Cesca Therapeutics stock. Vanguard Group Inc. raised its stake in Cesca Therapeutics Inc (NASDAQ:KOOL) by 34.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 61,521 shares of the biotechnology company’s stock after buying an additional 15,828 shares during the period. Vanguard Group Inc. owned 0.62% of Cesca Therapeutics worth $200,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.30% of the company’s stock.
About Cesca Therapeutics
Cesca Therapeutics Inc is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.
What are top analysts saying about Cesca Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cesca Therapeutics Inc and related companies.